Company: CRL
Filing Date: 2025-02-21
Form Type: 8-K
Source: 0001100682-25-000014
Chunk: 0

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-21
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

Purchase of Shares of Company Common Stock

On February 20, 2025:

• Mr. James C. Foster, Chair, President and Chief Executive Officer of Charles River Laboratories International, Inc. (the “ Company”) purchased 6,075 shares of the Company’s common stock at an average price of $165.01 for an aggregate purchase price of approximately $1 million in open market transactions.

• Ms. Birgit Girshick, Corporate Executive Vice President and Chief Operating Officer of the Company purchased 1,514 shares of the Company’s common stock at an average price of $164.63 for an aggregate purchase price of approximately $250,000 in open market transactions.

Both Mr. Foster and Ms. Girshick indicated that they engaged in these transactions in recognition of the confidence they have in the strategic direction and long-term growth prospects of the Company. Mr. Foster’s and Ms. Girshick's purchases will be reported separately on Forms 4 to be filed with the Securities and Exchange Commission.

Termination of Rule 10b5-1 Trading Plans

On February 19, 2025:

• Mr. Foster terminated his Rule 10b5-1 Trading Plan (the “ Foster Plan”) dated February 26, 2024. The Foster Plan allowed for the sale of a maximum of 129,721 shares of the Company’s common stock at times specified in the Foster Plan pursuant to a pre-established formula. Mr. Foster terminated the Foster Plan in order to facilitate the purchase of shares of common stock of the Company on February 20, 2025, as described above, without concern of unintentionally violating short swing profit rules of Section 16 of the Securities Exchange Act of 1934, as amended, by affecting open market sales within six months of open market purchases. Mr. Foster sold 25,000 shares pursuant to the Foster Plan on August 1, 2024.

• Ms. Girshick terminated her Rule 10b5-1 Trading Plan (the “ Girshick Plan”) dated November 22, 2023. The Girshick Plan allowed for the sale of a maximum of 22,362 shares of the Company’s common stock at times specified in the Girshick Plan pursuant to a pre-established formula. Ms. Girshick terminated the Girshick Plan in order to facilitate the purchase of shares of common stock of the Company on February 20, 2025, as described above, without concern